Unicycive

We’re entering the new year with a renewed commitment to transforming . Our Senior Director of Insights and Analytics, Anne Marie Schauman, shares more about what continues to push our team forward in innovating for the kidney disease community.

Yesterday at we presented results for our investigational phosphate binder for patients with chronic kidney disease (CKD). The findings showed significant reductions in both pill volume and pill burden for CKD patients with hyperphosphatemia. Learn more about our key findings and what it could mean for patients who struggle to improve phosphate control: https://unicycive.com/oxylanthanum-carbonate-achieves-serum-phosphate-control-with-significantly-lower-pill-burden-in-dialysis-patients-with-hyperphosphatemia/